Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today hi
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 27'th May 2026
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation Launch
06:08pm, Tuesday, 12'th May 2026
Axsome Therapeutics NASDAQ: AXSM executives said the company is preparing for a June launch of AUVELITY in Alzheimer's disease agitation while continuing to expand its push in major depressive disorde
Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
02:20pm, Tuesday, 12'th May 2026
Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
3 Stocks Poised to Disrupt the Healthcare Market by 2030
07:30am, Friday, 08'th May 2026
The old healthcare model is breaking down.
Axsome Therapeutics Recognizes Mental Health Month
07:00am, Thursday, 07'th May 2026
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales
01:50pm, Tuesday, 05'th May 2026
Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.
3 Overlooked Stocks Set to Soar in 2026
08:45am, Tuesday, 05'th May 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 05'th May 2026
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
03:43pm, Monday, 04'th May 2026
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Why Did Axsome Therapeutics Stock Hit Another Record High Today?
03:10pm, Monday, 04'th May 2026
Investors think a new addition to the biotech's pipeline could be the next catalyst.
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied
12:32pm, Monday, 04'th May 2026
Axsome Therapeutics, Inc. is rated Hold, as revenue growth and pipeline promise are offset by sequential declines and ongoing losses. AXSM's Q1 revenues grew 57% year-on-year to $191m, but both Auveli
Here's What Key Metrics Tell Us About Axsome (AXSM) Q1 Earnings
10:30am, Monday, 04'th May 2026
Although the revenue and EPS for Axsome (AXSM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street e
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates
09:15am, Monday, 04'th May 2026
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.8 per share a year ago.
